Video Coming Soon
Comparing your drug and the competition in terms of efficacy and safety data in the targeted therapeutic area is critically essential for optimizing development strategies and maximizing the value of a new drug. Model-based meta-analysis (MBMA) with clinical outcome database of publications and external information has been utilized to optimize trial design in recent years.
Certara’s CODEx Clinical Outcome Database provides datasets and a visualization platform for more than 60 therapeutic areas, which are collected by Certara’s experts following SOPs. We strongly support you to adopt MBMA in drug development with MBMA services provided by our consulting team.
In the webinar, we will highlight the latest MBMA case studies as well as a benefit of CODEx database. In addition, we will walk through Certara.AI, a life science-focused AI technology that enables clinical researchers to collect internal and external literature data efficiently.
Note: The webinar will be available only in Japanese.
Speaker:
Mayumi Hasegawa, Sr. Director, Drug Development Service, Certara
Takanori Ogawa, Solutions Consultant, Certara